On October 25, 2023, Lipella Pharmaceuticals Inc. closed the transaction. The company has received $2,000,000 pursuant to Regulation D and included participation from single investor.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7256 USD | +0.08% | +1.33% | -28.86% |
Apr. 17 | Lipella Pharmaceuticals Inc. Appoints Jason Hafron and Pradeep Tyagi to Scientific Advisory Board | CI |
Apr. 09 | Maxim Initiates Lipella Pharmaceuticals at Buy Rating With $2 Price Target | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-28.86% | 5.1M | |
-3.22% | 102B | |
+1.42% | 96.29B | |
+2.13% | 22.18B | |
-15.82% | 21.2B | |
-9.21% | 18.31B | |
-39.98% | 17.38B | |
-14.53% | 16.36B | |
+4.53% | 13.97B | |
+32.28% | 12.17B |
- Stock Market
- Equities
- LIPO Stock
- News Lipella Pharmaceuticals Inc.
- Lipella Pharmaceuticals Inc. announced that it has received $1.998685 million in funding